2022
DOI: 10.1016/j.neuropharm.2022.109211
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacological strategies for post-traumatic stress disorder (PTSD): From animal to clinical studies

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
10
0
2

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 19 publications
(12 citation statements)
references
References 235 publications
0
10
0
2
Order By: Relevance
“…Methylone is a structurally similar, beta-ketone analog of MDMA, so the similarities and differences between the two compounds should be considered when putting our new data into context. MDMA-assisted psychotherapy significantly alleviates symptoms of PTSD ( 7 ), a condition for which antidepressants (sertraline and paroxetine) are the only approved treatments ( 33 ). In contrast to methylone, MDMA has been well-studied using both binge-dosing paradigms and lower therapeutic doses in preclinical species.…”
Section: Discussionmentioning
confidence: 99%
“…Methylone is a structurally similar, beta-ketone analog of MDMA, so the similarities and differences between the two compounds should be considered when putting our new data into context. MDMA-assisted psychotherapy significantly alleviates symptoms of PTSD ( 7 ), a condition for which antidepressants (sertraline and paroxetine) are the only approved treatments ( 33 ). In contrast to methylone, MDMA has been well-studied using both binge-dosing paradigms and lower therapeutic doses in preclinical species.…”
Section: Discussionmentioning
confidence: 99%
“…There are currently no approved pharmacotherapies for cocaine, amphetamine, cannabis, or benzodiazepine use disorders. Sertraline and paroxetine, the only two approved medications for PTSD, have shown only modest effects in PTSD (18). Similarly, while multiple behavioral therapies for combined PTSD and substance use disorders have been explored (i.e., cognitive behavioral therapy, mindfulness based therapies, and prolonged exposure therapy), treatment outcomes remain limited (19).…”
Section: Open Access Edited Bymentioning
confidence: 99%
“…Effective drugs for the treatment of these disorders are tricyclic antidepressants (TCAs; Zohar and Westenberg, 2007 ; Puetz et al, 2015 ), reversible and irreversible monoamine oxidase inhibitors (MAOIs; Liebowitz et al, 1990 ; Chamberlain and Baldwin, 2021 ), benzodiazepines (Steenen et al, 2016 ), selective serotonin reuptake inhibitor (SSRIs; Zohar and Westenberg, 2007 ), and antiepileptic drugs (Berlin, 2007 ; Gasparyan et al, 2022 ). TCAs and MAOIs are effective for treatment but have high side effects, thus limiting their use.…”
Section: Perspective On the Treatment Of Trauma And Fear-related Diso...mentioning
confidence: 99%